| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(86)90355-7 |
| P698 | PubMed publication ID | 2875236 |
| P2093 | author name string | P Jones | |
| R G Luke | |||
| A G Diethelm | |||
| J J Curtis | |||
| J D Whelchel | |||
| E Dubovsky | |||
| P2860 | cites work | Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats | Q37557942 |
| Quantitation of renal function with glomerular and tubular agents | Q40251645 | ||
| New formulas for the calculation of effective renal plasma flow. | Q52434774 | ||
| Reversibility of cyclosporin nephrotoxicity after three months' treatment | Q69856306 | ||
| Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients | Q69885494 | ||
| Chronic irreversible nephrotoxicity from cyclosporin A | Q69905953 | ||
| Neural Degeneration and Regeneration in Human Renal Transplants | Q69909583 | ||
| A Randomized Clinical Trial of Cyclosporine in Cadaveric Renal Transplantation | Q70277015 | ||
| Cyclosporine-associated chronic nephropathy | Q70376376 | ||
| The effect of salt intake on cyclosporine-induced impairment of renal function in rats | Q70392471 | ||
| Effect of cyclosporin on renin-angiotensin-aldosterone system | Q72540008 | ||
| P433 | issue | 8505 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 477-479 | |
| P577 | publication date | 1986-08-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Cyclosporin in therapeutic doses increases renal allograft vascular resistance. | |
| P478 | volume | 2 |
| Q46702756 | A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. |
| Q28316922 | A trial of the prostaglandin E1 analogue, enisoprost, to reverse chronic cyclosporine-associated renal dysfunction |
| Q73269876 | Acute cardiovascular effects of intravenous cyclosporine |
| Q69409511 | Acute cyclosporine renal dysfunction reversed by dopamine infusion in healthy subjects |
| Q34726568 | Acute tubular necrosis in kidney transplant patients treated with enalapril |
| Q39643104 | Adverse reactions and interactions of cyclosporin |
| Q38795351 | Alisol F 24 Acetate Enhances Chemosensitivity and Apoptosis of MCF-7/DOX Cells by Inhibiting P-Glycoprotein-Mediated Drug Efflux. |
| Q33349234 | Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis |
| Q36816317 | Characteristics of cadaveric renal allograft recipients developing chronic rejection |
| Q41184484 | Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy |
| Q35579156 | Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation |
| Q41201529 | Clinically significant drug interactions with cyclosporin. An update |
| Q36062030 | Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens |
| Q38772748 | Complications after cardiac transplantation. The role of immunosuppression. |
| Q38241710 | Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients |
| Q74685764 | Conversion from cyclosporine to tacrolimus in renal allograft recipients with chronic graft nephropathy: preliminary report |
| Q73304028 | Conversion from cyclosporine to tacrolimus in renal allograft recipients with delayed graft function from severe acute tubular necrosis |
| Q72952699 | Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants |
| Q40380386 | Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation |
| Q73288512 | Culture of human renal tubular cells: positive selection of kallikrein-containing cells |
| Q33558294 | Current status of renal transplantation |
| Q46640727 | Cyclosporin A generates superoxide in smooth muscle cells |
| Q44186344 | Cyclosporin A-related Raynaud's phenomenon in a renal transplant recipient |
| Q44416550 | Cyclosporin and Raynaud phenomenon |
| Q68039376 | Cyclosporin reduces renal prostanoid excretion in type 1 diabetic patients |
| Q41775618 | Cyclosporin therapy in vivo attenuates the response to vasodilators in the isolated perfused kidney of the rabbit |
| Q73327031 | Cyclosporine A and purinergic receptors in rat kidney |
| Q39699974 | Cyclosporine conversion |
| Q44111129 | Cyclosporine nephrotoxicity and the role of cyclosporine in living-related donor transplantation |
| Q68461377 | Cyclosporine-associated hypertension |
| Q57704640 | Cyclosporine-induced renal dysfunction in experimental animals and humans |
| Q39673279 | Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors |
| Q71076792 | Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients |
| Q42158913 | Does nifedipine ameliorate cyclosporin A nephrotoxicity? |
| Q41431134 | Drug nephrotoxicity: an overview |
| Q37939583 | Drug-induced nephropathies |
| Q37740051 | Drug-induced nephrotoxicity. Aetiology, clinical features and management |
| Q73277978 | Effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients |
| Q42501379 | Effect of cyclosporin A on nitric oxide production in cultured LLC-PK1 cells |
| Q39680233 | Effect of cyclosporine on the kidney |
| Q54158264 | Effect of felodipine on renal haemodynamics and tubular sodium handling after single-dose cyclosporin infusion in renal transplant recipients treated with azathioprine and prednisolone. |
| Q35876331 | Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk |
| Q52872533 | Effect of oral cyclosporin on renal function in Crohn's disease. |
| Q42705677 | Effects of a selective adenosine A1 receptor antagonist on the development of cyclosporin nephrotoxicity |
| Q73321788 | Effects of cyclosporine A on the regenerating endothelium following direct arterial injury |
| Q28335574 | Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine |
| Q69928102 | Endothelin and cyclosporin nephrotoxicity |
| Q70191679 | Endothelium-derived relaxing and contracting factors: perspectives in nephrology |
| Q37712655 | Erythropoiesis and erythropoietin levels in renal transplant recipients |
| Q72294723 | Experience with not offering dialysis to patients with a poor prognosis |
| Q67516915 | Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients |
| Q79299819 | Haemodynamic changes in human kidney allografts following administration of nifedipine: assessment with doppler spectrum analysis |
| Q36873134 | Hypertension after renal transplant |
| Q40725244 | Hypertension following kidney transplantation |
| Q42206798 | Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent |
| Q39656189 | Hypertension in renal transplant recipients |
| Q33804467 | Immunosuppressant-induced nephropathy: pathophysiology, incidence and management |
| Q33908046 | Immunosuppressive drugs: the first 50 years and a glance forward |
| Q44033348 | Improvement of renal graft function after conversion from a calcineurin inhibitor including immunosuppression to a mycophenolate sodium including regimen: a 4-year follow-up |
| Q72898085 | Increased platelet-derived growth factor in the kidneys of cyclosporin-treated rats |
| Q69535486 | Influence of nicardipine on renal function and plasma cyclosporin in renal transplant patients |
| Q54284628 | Kidney function of patients with healthy kidneys during cyclosporin treatment |
| Q34572738 | Long-term outcome after liver transplantation in children |
| Q43955490 | Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial |
| Q35349065 | Mechanisms and amelioration of acute renal allograft failure in the cyclosporine era |
| Q34607590 | Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection |
| Q73453363 | Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future |
| Q77175919 | Optimization of cyclosporine therapy in renal transplantation |
| Q40920731 | Pharmacology of immunosuppressive medications used in renal diseases and transplantation |
| Q74685731 | Preoperative induction with tacrolimus does not have a detrimental effect on primary graft function in adult cadaveric renal transplantation |
| Q35778585 | President's address: salt-too much of a good thing? |
| Q38015284 | Principles of immunosuppression. |
| Q41093663 | Protective effects of diltiazem and the prostazycline analogue iloprost in human renal transplantation |
| Q33774364 | Quantitation of allograft fibrosis and chronic allograft nephropathy. |
| Q39487982 | Radionuclide evaluation of renal transplants |
| Q72155531 | Radionuclide evaluation of renal transplants |
| Q40743649 | Renal actions of endothelin: linking cellular signaling pathways to kidney disease |
| Q58812471 | Sequential effects of cyclosporine therapy on blood pressure, renal function and neurohormones |
| Q41549146 | Switching between cyclosporin formulations. What are the risks? |
| Q90136673 | The Many Faces of Calcineurin Inhibitor Toxicity-What the FK? |
| Q56988171 | The endothelin system in the kidney |
| Q52395071 | The fractional excretion of urea: a new diagnostic test for acute renal allograft rejection. |
| Q38003049 | The impact of donor-specific anti-HLA antibodies on late kidney allograft failure |
| Q68606113 | The pathophysiology of Sandimmune (cyclosporine) in man and animals |
| Q44249667 | The restoration of ATP synthesis may explain the protective effect of calcium antagonists against cyclosporine a nephrotoxicity |
| Q33957200 | The use of mycophenolate mofetil in transplant recipients |
| Q41478142 | The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations |
| Q35975872 | The utility of cyclosporine weaning in renal transplantation |
| Q54174772 | Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. |
| Q44800871 | Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy |
Search more.